DataSheet_1_Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field.zip

ObjectiveThe study was designed to explore the evolution of non-small cell lung cancer (NSCLC) management in the last 20 years.MethodsThe top 100 most-cited papers on NSCLC treatment were retrieved from the Web of Science Core Collection database. R and VOSviewer were used to extract bibliographic information, including the year of publication, countries/regions, institutions, authors, journals, keywords, impact factor, and total citations. The topic and type of papers were checked independently by authors. Bibliometric analysis was conducted and visualized with R, CiteSpace, Excel and VOSviewer to identify output dynamics, research forces, topics, hotspots, and frontiers in the field.ResultsThe average citation of each retrieved top 100 most-cited NSCLC management papers was 1,725 (range: 615-7,340). Fifty-seven corresponding authors were from the United States. This country contributed the most papers (n=76), followed by Germany (n=34), France (n=33), and South Korea (n=32). The top contributors were Paz-Ares L. (n=12) and Reck M. (n=12). The Memorial Sloan Kettering Cancer Center published the largest number of papers (n=20). There were two significant citation paths, indicating publications in medicine/medical/clinical journals primarily cited journals in molecular/biology/genetics fields, partly cited health/nursing/medicine fields. Top-cited papers mainly came from the New England Journal of Medicine (n=33, citations=80,427), followed closely by the Journal of Clinical Oncology (n=28, citations=32,408). “Chemotherapy” (n=36) was the keyword with the greatest frequency of co-occurrence. “Open-label” was the keyword with the strongest burst strength (=4.01), followed by “nivolumab” (=3.85), “blockade” (=2.86), and “efficacy” (=2.85).ConclusionsThe United States as a nation and the Memorial Sloan Kettering Cancer Center as an institute contributed the most to this field. The New England Journal of Medicine is the most eye-catching journal. Hotspots of NSCLC management have almost undergone an evolution from chemotherapy and radiotherapy to targeted therapy to immunotherapy. Molecular/biological/genetic fields become the main research base for NSCLC treatment. Immunotherapy and combination therapy are research frontiers.

研究旨在探讨过去20年来非小细胞肺癌（NSCLC）诊疗模式的演变。研究方法为从Web of Science核心合集数据库中检索到NSCLC治疗领域的100篇最高被引论文。利用R和VOSviewer软件提取了包括出版年份、国家/地区、机构、作者、期刊、关键词、影响因子和总引用次数等文献信息。论文的主题和类型由作者独立审核。通过R、CiteSpace、Excel和VOSviewer进行文献计量分析并可视化，以识别该领域的产出动态、研究力量、主题、热点和前沿。研究结果揭示，所检索的100篇最高被引NSCLC管理论文的平均引用次数为1,725次（范围：615-7,340次）。其中，来自美国的57位对应作者贡献了最多的论文（共76篇），紧随其后的是德国（34篇）、法国（33篇）和韩国（32篇）。Paz-Ares L.（共12篇）和Reck M.（共12篇）为最大的贡献者。纪念斯隆-凯特琳癌症中心发表了最多的论文（共20篇）。存在两个显著的引用路径，表明发表在医学/医学/临床期刊上的出版物主要引用了分子/生物学/遗传学领域的期刊，部分引用了健康/护理/医学领域。最高被引论文主要来自《新英格兰医学杂志》（共33篇，引用次数为80,427次），其次是《临床肿瘤学杂志》（共28篇，引用次数为32,408次）。关键词“化疗”（共36次）是共现频率最高的，其次是“开放标签”（爆发强度为4.01），随后是“nivolumab”（3.85）、“阻断”（2.86）和“疗效”（2.85）。结论表明，美国作为国家以及纪念斯隆-凯特琳癌症中心作为研究机构对该领域贡献最大。《新英格兰医学杂志》是最受瞩目的期刊。NSCLC管理领域的热点几乎经历了从化疗和放疗到靶向治疗再到免疫治疗的演变。分子/生物学/遗传学领域成为NSCLC治疗的主要研究基地。免疫治疗和联合治疗是研究的前沿领域。